Leong SL, Zainudin R, Kazan-Allen L, Robinson BW. Asbestos in Asia. Respirology. 2015;20(4):548–55.
Castranova V, Vallyathan V. Silicosis and coal workers' pneumoconiosis. Environ Health Perspect. 2000;108(Suppl 4):675–84.
Courtice MN, Lin S, Wang X. An updated review on asbestos and related diseases in China. Int J Occup Environ Health. 2012;18(3):247–53.
Zhang M, Wang D, Zheng YD, XY DU, Chen SY. Analyses on the characteristics and the trends of pneumoconiosis notified between 1997 and 2009 in China. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2013;31(5):321–34.
Pandey JK, Agarwal D. Biomarkers. A potential prognostic tool for silicosis. Indian J Occup Environ Med. 2012;16:101–7.
Takahashi T, Munakata M, Suzuki I, Kawakami Y. Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 1998;158, 1294:–8.
Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165:378–81.
Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, Hirasawa Y, Hiwada K. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1680–4.
Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med. 2006;260:429–34.
Yamakawa H, Hagiwara E, Kitamura H, Yamanaka Y, Ikeda S, Sekine A, Baba T, Okudela K, Iwasawa T, Takemura T, Kuwano K, Ogura T. Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease. J Thorac Dis. 2017;9(2):362–71.
Nishikiori H, Chiba H, Ariki S, Kuronuma K, Otsuka M, Shiratori M, Ikeda K, Watanabe A, Kuroki Y, Takahashi H. Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2014;14:196.
Takahashi H, Sano H, Chiba H, Kuroki Y. Pulmonary surfactant proteins A and D: innate immune functions and biomarkers for lung diseases. Curr Pharm Des. 2006;12(5):589–98.
Craig VJ, Zhang L, Hagood JS, Owen CA. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2015;53(5):585–600.
Selman M, Ruiz V, Cabrera S, Segura L, Ramirez R, Barrios R, Pardo A. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis: a prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol. 2000;279:L562–74.
Morais A, Beltrão M, Sokhatska O, Costa D, Melo N, Mota P, Marques A, Delgado L. Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias. Respir Med. 2015;109:1063–8.
Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA. 2002;99:6292–7.
Henry MT, McMahon K, Mackarel AJ, Prikk K, Sorsa T, Maisi P, Sepper R, Fitzgerald MX, O’Connor CM. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur Respir J. 2002;20:1220–7.
Prince P, Boulay ME, Pagé N, Desmeules M, Boulet LP. Induced sputum markers of fibrosis and decline in pulmonary function in asbestosis and silicosis: a pilot study. Int J Tuberc Lung Dis. 2008;12:813–9.
Jiang PR, Cao Z, Qiu ZL, Pan JW, Zhang N, Wu YF. Plasma levels of TNF-α and MMP-9 in patients with silicosis. Eur Rev Med Pharmacol Sci. 2015;19:1716–20.
Pingle SK, Tumane RG, Jawade AA. Neopterin: Biomarker of cell-mediated immunity and potent usage as biomarker in silicosis and other occupational diseases. Indian J Occup Environ Med. 2008;12:107–11.
Miao R, Ding B, Zhang Y, Xia Q, Li Y, Zhu B. Proteomic profiling change during the early development of silicosis disease. J Thorac Dis. 2016;8:329–41.
International Labour Office. International Classification of Radiographs of Pneumoconiosis, revised. Occupational Safety and Health Series. 2011;22:Rev 2011.
Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity), report working party standardization of lung function tests, European Community for steel and coal: official statement of the European Respiratory Society. Eur Respir J. 1993;6:41–53.
Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch JP 3rd, Toews G. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol. 1997;169:977–83.
Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun. 2005;338:1845–52.
Wakamatsu K, Nagata N, Kumazoe H, Oda K, Ishimoto H, Yoshimi M, Takata S, Hamada M, Koreeda Y, Takakura K, Ishizu M, Hara M, Ise S, Izumi M, Akasaki T, Maki S, Kawabata M, Mukae H, Kawasaki M. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Investig. 2017;55:16–23.
Hu Y, Wang LS, Jin YP, Du SS, Du YK, He X, Weng D, Zhou Y, Li QH, Shen L, Zhang F, Su YL, Sun XL, Ding JJ, Zhang WH, Cai HR, Dai HP, Dai JH, Li HP. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients. Clin Respir J. 2017;11(3):337–45.
Kishaba T, Shimaoka Y, Fukuyama H, Yoshida K, Tanaka M, Yamashiro S, Tamaki H. A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibrosis and emphysema. BMJ Open. 2012;15:2(3).
Ariki S, Nishitani C, Kuroki Y. Diverse functions of pulmonary collectins in host defense of the lung. J Biomed Biotechnol. 2012;2012:532071.
Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, Hiratori M, Kuroki Y, Abe S. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationshipto disease extent. Am J Respir Crit Care Med. 2000;162(3 Pt 1):1109–14.
Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, Nagae H, Mason RJ. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002;19(3):439–46.
Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5:e93.
Craig VJ, Polverino F, Laucho-Contreras ME, Shi Y, Liu Y, Osorio JC, Tesfaigzi Y, Pinto-Plata V, Gochuico BR, Rosas IO, et al. Mononuclear phagocytes and airway epithelial cells: novel sources of matrix metalloproteinase-8 (MMP-8) in patients with idiopathic pulmonary fibrosis. PLoS One. 2014;9:e97485.
Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013;143(5):1422–9.
Akira M, Morinaga K. The comparison of high-resolution computed tomography findings in asbestosis and idiopathic pulmonary fibrosis. Am J Ind Med. 2016;59:301–6.
Arakawa H, Kishimoto T, Ashizawa K, Kato K, Okamoto K, Honma K, Hayashi S, Akira M. Asbestosis and other pulmonary fibrosis in asbestos-exposed workers: high-resolution CT features with pathological correlations. Eur Radiol. 2016;26:1485–92.
Yang XL, Zhu XL, Li A, Du XQ, Song YG, Ye Q. Characteristics of lung function in patients with asbestosis of different stages. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2016;34:687–90.
Gothi D, Gahlot T, Sah RB, Saxena M, Ojha UC, Verma AK, Spalgais S. Asbestos-induced lung disease in small-scale clutch manufacturing workers. Indian J Occup Environ Med. 2016;20:95–102.